Bicon’s Biopharma business continued to be the key growth driver during the quarter, with revenue rising 17% year-on-year to ₹3,615 crore. Biosimilars revenue grew 16% to ₹2,855 crore, while generics revenue increased 21% to ₹760 crore, aided by momentum from recent biosimilar and generic product launches across key markets.
